Please enable JavaScript to continue using this application.

Compare $AKTS vs $JANX | Chartloom

Compare

$AKTS vs $JANX

Aktis Oncology Inc · Janux Therapeutics Inc

AKTS

Aktis Oncology Inc

JANX

Janux Therapeutics Inc

Compare $AKTS vs $JANX

Comparing Aktis Oncology Inc and Janux Therapeutics Inc

AKTSAktis Oncology Inc

JANXJanux Therapeutics Inc

AKTSAktis Oncology Inc

Market cap

$969M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

99.47x

Rev growth (TTM)

49.9%

YTD performance

-19.0%

52W performance

18688.8%

FCF yield

-12.6%

JANXJanux Therapeutics Inc

Market cap

$1.12B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

63.26x

Rev growth (TTM)

5367.0%

YTD performance

34.7%

52W performance

-24.0%

FCF yield

-3.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKTS

JANX

Detailed metrics comparison

AKTS

Aktis Oncology Inc

JANX

Janux Therapeutics Inc

Market Cap

AKTS$969M

JANX$1.12B

Enterprise Value

AKTS$887M

JANX$1.09B

Price

AKTS$18.15

JANX$18.39

P/E Ratio

AKTSN/A

JANXN/A

P/S Ratio

AKTS73.94x

JANX46.73x

EV/Sales

AKTS67.65x

JANX45.57x

EV/EBITDA

AKTS0.00x

JANX0.00x

P/B Ratio

AKTS2.12x

JANX1.12x

P/FCF Ratio

AKTSN/A

JANXN/A

EV/FCF

AKTS-7.29x

JANX-26.09x

PEG Ratio

AKTSN/A

JANXN/A

Forward P/E (NTM)

AKTSN/A

JANXN/A

Forward P/S (NTM)

AKTS99.47x

JANX63.26x

Revenue (TTM)

AKTS$13M

JANX$24M

Revenue Growth (YoY)

AKTS49.9%

JANX5367.0%

Forward Rev Growth

AKTS-9.8%

JANX-76.0%

Gross Margin (TTM)

AKTS0.0%

JANX0.0%

Operating Margin (TTM)

AKTS0.0%

JANX0.0%

EBITDA Margin (TTM)

AKTS-934.0%

JANX-590.2%

Net Margin (TTM)

AKTS-810.2%

JANX-427.5%

FCF Margin (TTM)

AKTS-928.1%

JANX-174.7%

Net Income (TTM)

AKTS$-106M

JANX$-103M

FCF (TTM)

AKTS$-122M

JANX$-42M

EPS (TTM)

AKTS-$1.92

JANX-$1.63

ROE (TTM)

AKTS-3080.0%

JANX-1079.0%

ROA (TTM)

AKTS-2531.0%

JANX-1010.0%

ROIC (TTM)

AKTS-3080.0%

JANX-1079.0%

Cash

AKTS$82M

JANX$28M

Debt

AKTS$0

JANX$0

Net Cash/Debt

AKTS$82M

JANX$28M

Current Ratio (TTM)

AKTS16.33x

JANX16.35x

Quick Ratio (TTM)

AKTS16.10x

JANX16.25x

Debt/Equity (TTM)

AKTS0.00x

JANX0.00x

Debt/Assets (TTM)

AKTS0.0%

JANX0.0%

Interest Coverage (TTM)

AKTSN/A

JANXN/A

Net Debt/EBITDA (TTM)

AKTS0.00x

JANX0.00x

Beta

AKTS160.56

JANX2.42

52W Performance

AKTS18688.8%

JANX-24.0%

YTD Performance

AKTS-19.0%

JANX34.7%

% from 52W High

AKTS-46.9%

JANX-48.0%

% from 52W Low

AKTS907400.0%

JANX51.7%

Asset Turnover (TTM)

AKTS0.03x

JANX0.02x

FCF Yield (TTM)

AKTS-12.6%

JANX-3.7%

Earnings Yield (TTM)

AKTS-11.0%

JANX-9.1%

Dividend Yield (TTM)

AKTSN/A

JANXN/A

Rule of 40

AKTS-878.2

JANX5,192.3

EV/GP/RG

AKTSN/A

JANXN/A

Ticker research

View AKTS research View JANX research

Metric	AKTS Aktis Oncology Inc	JANX Janux Therapeutics Inc
Market & Valuation
Market Cap	$969M	$1.12B
Enterprise Value	$887M	$1.09B
Price	$18.15	$18.39
P/E Ratio	N/A	N/A
P/S Ratio	73.94x	46.73x
EV/Sales	67.65x	45.57x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.12x	1.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.29x	-26.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	99.47x	63.26x
Revenue & Growth
Revenue (TTM)	$13M	$24M
Revenue Growth (YoY)	49.9%	5367.0%
Forward Rev Growth	-9.8%	-76.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-934.0%	-590.2%
Net Margin (TTM)	-810.2%	-427.5%
FCF Margin (TTM)	-928.1%	-174.7%
Net Income (TTM)	$-106M	$-103M
FCF (TTM)	$-122M	$-42M
EPS (TTM)	-$1.92	-$1.63
ROE (TTM)	-3080.0%	-1079.0%
ROA (TTM)	-2531.0%	-1010.0%
ROIC (TTM)	-3080.0%	-1079.0%
Financial Health
Cash	$82M	$28M
Debt	$0	$0
Net Cash/Debt	$82M	$28M
Current Ratio (TTM)	16.33x	16.35x
Quick Ratio (TTM)	16.10x	16.25x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	160.56	2.42
52W Performance	18688.8%	-24.0%
YTD Performance	-19.0%	34.7%
% from 52W High	-46.9%	-48.0%
% from 52W Low	907400.0%	51.7%
Efficiency & Yields
Asset Turnover (TTM)	0.03x	0.02x
FCF Yield (TTM)	-12.6%	-3.7%
Earnings Yield (TTM)	-11.0%	-9.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-878.2	5,192.3
EV/GP/RG	N/A	N/A
Ticker research	View AKTS research	View JANX research

Valuation

P/S Ratio

JANX

46.73x

AKTS

73.94x

EV/FCF

JANX

-26.09x

AKTS

-7.29x

Growth & revenue

Revenue Growth TTM

JANX

5367.0%

AKTS

49.9%

Forward Revenue Growth

AKTS

-9.8%

JANX

-76.0%

Profitability & performance

Gross Margin

AKTS

0.0%

JANX

0.0%

ROE

JANX

-1079.0%

AKTS

-3080.0%

FCF Yield %

JANX

-3.7%

AKTS

-12.6%

52-Week Performance

AKTS

18688.8%

JANX

-24.0%

Detailed metrics comparison

AKTS

Aktis Oncology Inc

JANX

Janux Therapeutics Inc

Market Cap

AKTS$969M

JANX$1.12B

Enterprise Value

AKTS$887M

JANX$1.09B

Price

AKTS$18.15

JANX$18.39

P/E Ratio

AKTSN/A

JANXN/A

P/S Ratio

AKTS73.94x

JANX46.73x

EV/Sales

AKTS67.65x

JANX45.57x

EV/EBITDA

AKTS0.00x

JANX0.00x

P/B Ratio

AKTS2.12x

JANX1.12x

P/FCF Ratio

AKTSN/A

JANXN/A

EV/FCF

AKTS-7.29x

JANX-26.09x

PEG Ratio

AKTSN/A

JANXN/A

Forward P/E (NTM)

AKTSN/A

JANXN/A

Forward P/S (NTM)

AKTS99.47x

JANX63.26x

Revenue (TTM)

AKTS$13M

JANX$24M

Revenue Growth (YoY)

AKTS49.9%

JANX5367.0%

Forward Rev Growth

AKTS-9.8%

JANX-76.0%

Gross Margin (TTM)

AKTS0.0%

JANX0.0%

Operating Margin (TTM)

AKTS0.0%

JANX0.0%

EBITDA Margin (TTM)

AKTS-934.0%

JANX-590.2%

Net Margin (TTM)

AKTS-810.2%

JANX-427.5%

FCF Margin (TTM)

AKTS-928.1%

JANX-174.7%

Net Income (TTM)

AKTS$-106M

JANX$-103M

FCF (TTM)

AKTS$-122M

JANX$-42M

EPS (TTM)

AKTS-$1.92

JANX-$1.63

ROE (TTM)

AKTS-3080.0%

JANX-1079.0%

ROA (TTM)

AKTS-2531.0%

JANX-1010.0%

ROIC (TTM)

AKTS-3080.0%

JANX-1079.0%

Cash

AKTS$82M

JANX$28M

Debt

AKTS$0

JANX$0

Net Cash/Debt

AKTS$82M

JANX$28M

Current Ratio (TTM)

AKTS16.33x

JANX16.35x

Quick Ratio (TTM)

AKTS16.10x

JANX16.25x

Debt/Equity (TTM)

AKTS0.00x

JANX0.00x

Debt/Assets (TTM)

AKTS0.0%

JANX0.0%

Interest Coverage (TTM)

AKTSN/A

JANXN/A

Net Debt/EBITDA (TTM)

AKTS0.00x

JANX0.00x

Beta

AKTS160.56

JANX2.42

52W Performance

AKTS18688.8%

JANX-24.0%

YTD Performance

AKTS-19.0%

JANX34.7%

% from 52W High

AKTS-46.9%

JANX-48.0%

% from 52W Low

AKTS907400.0%

JANX51.7%

Asset Turnover (TTM)

AKTS0.03x

JANX0.02x

FCF Yield (TTM)

AKTS-12.6%

JANX-3.7%

Earnings Yield (TTM)

AKTS-11.0%

JANX-9.1%

Dividend Yield (TTM)

AKTSN/A

JANXN/A

Rule of 40

AKTS-878.2

JANX5,192.3

EV/GP/RG

AKTSN/A

JANXN/A

Ticker research

View AKTS research View JANX research

Metric	AKTS Aktis Oncology Inc	JANX Janux Therapeutics Inc
Market & Valuation
Market Cap	$969M	$1.12B
Enterprise Value	$887M	$1.09B
Price	$18.15	$18.39
P/E Ratio	N/A	N/A
P/S Ratio	73.94x	46.73x
EV/Sales	67.65x	45.57x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.12x	1.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.29x	-26.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	99.47x	63.26x
Revenue & Growth
Revenue (TTM)	$13M	$24M
Revenue Growth (YoY)	49.9%	5367.0%
Forward Rev Growth	-9.8%	-76.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-934.0%	-590.2%
Net Margin (TTM)	-810.2%	-427.5%
FCF Margin (TTM)	-928.1%	-174.7%
Net Income (TTM)	$-106M	$-103M
FCF (TTM)	$-122M	$-42M
EPS (TTM)	-$1.92	-$1.63
ROE (TTM)	-3080.0%	-1079.0%
ROA (TTM)	-2531.0%	-1010.0%
ROIC (TTM)	-3080.0%	-1079.0%
Financial Health
Cash	$82M	$28M
Debt	$0	$0
Net Cash/Debt	$82M	$28M
Current Ratio (TTM)	16.33x	16.35x
Quick Ratio (TTM)	16.10x	16.25x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	160.56	2.42
52W Performance	18688.8%	-24.0%
YTD Performance	-19.0%	34.7%
% from 52W High	-46.9%	-48.0%
% from 52W Low	907400.0%	51.7%
Efficiency & Yields
Asset Turnover (TTM)	0.03x	0.02x
FCF Yield (TTM)	-12.6%	-3.7%
Earnings Yield (TTM)	-11.0%	-9.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-878.2	5,192.3
EV/GP/RG	N/A	N/A
Ticker research	View AKTS research	View JANX research